News | June 06, 2022
Proxygen and Merck collaborates to develop molecular glue degraders
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
The company has posted net loss of Rs. 67.65 crores for the Financial Year ended March 31, 2022
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
New Regional Processing Lab will serve Ahmedabad and the state of Gujarat
Susanne Kaestner joins the company as Senior Vice President, Quality and member of the Executive Team, and Dr. Thea Boehm as Vice President, Business Development.
A research group led by Ben-Gurion University of the Negev managed to produce an innovative microchip for creating sperm in a culture by using a microfluidic system.
The information center has been established with the aim of providing Fortis Healthcare’s world-class healthcare services accessible to the people of Tirupati.
Report lays out blueprint for achieving Organon’s purpose and business imperatives to help women and girls achieve their promise through better health
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
Innate to receive $5M milestone payment from AstraZeneca
Subscribe To Our Newsletter & Stay Updated
